Pharmacovigilance: post-authorisation

  • Email
  • Help

European Union (EU) legislation requires marketing authorisation holders, national competent authorities and the European Medicines Agency (EMA) to follow a number of pharmacovigilance processes after a product has been authorised.

Monitoring the safety of a medicine once it is on the market is the cornerstone of pharmacovigilance. The Agency provides extensive guidance to enable all stakeholders to meet their legal pharmacovigilance obligations.

United Kingdom’s (UK) withdrawal from the EU (new)

EMA has published important information to help users of the centralised procedure prepare for the expected consequences of 'Brexit', including their obligations related to establishment within the European Economic Area (EEA). For more information, see UK’s withdrawal from the EU.

In this section 


In other sections

Marketing authorisation holders should also consider the regulatory information in the sections below:

How helpful is this page?

Average rating:

 Based on 7 ratings

Add your rating:

See all ratings
1 ratings
0 ratings
1 ratings
1 ratings
4 ratings
    

Tell us more

Related content